MXCT
Live chart
What they do
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
For information only · Important disclosures
Grades vs sector
No sector grades for MXCT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.49 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.25 vs trailing $-0.34. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 1.5 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $33.0M | $-44.6M | $-36.2M |
| 2024 | $38.6M | $-41.1M | $-29.3M |
| 2023 | $41.3M | $-37.9M | $-25.4M |
| 2022 | $44.3M | $-23.6M | $-33.3M |
| 2021 | $33.9M | $-19.1M | $-14.5M |
| 2020 | $26.2M | $-11.8M | $-10.9M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -9.3%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | -0.09 | -0.08 | +14.3% |
| 2026-03-24 | -0.08 | -0.06 | +32.1% |
| 2025-11-12 | -0.10 | -0.09 | +12.2% |
| 2025-08-06 | -0.10 | -0.12 | -17.6% |
| 2025-05-07 | -0.10 | -0.10 | +2.4% |
| 2025-03-11 | -0.12 | -0.10 | +18.4% |
| 2024-11-06 | -0.12 | -0.11 | +11.3% |
| 2024-08-06 | -0.13 | -0.09 | +29.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $7.3M | -14.5% |
| 2026-03-31 | $9.7M | – |
| 2025-12-31 | $7.3M | – |
| 2025-09-30 | $6.8M | – |
| 2025-06-30 | $8.5M | – |
Analyst actions
PT $5
PT $9
PT $11
PT $11
Stats refreshed 2026-10-21 01:31:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026